Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II PK, PD, and safety study of AKP-022 versus relugolix in healthy Japanese premenopausal women
jRCT2071230042Phase 2Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of relugolix + estradiol + norethindrone and tissue-plasminogen activator (2 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Pharmacokinetics, Pharmacodynamics and 1 more. Started Aug 2023; status: completed.
02
Drugs
relugolix + estradiol + norethindronetissue-plasminogen activator
Beyond the preview
Go deeper on jRCT2071230042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230042.